Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing
protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer

Xu,Chun‑Wei; Wang,Gang; Wang,Wu‑Long; Gao,Wen‑Bin; Han,Chuan‑Jun; Gao,Jing‑Shan; Li,Yang; Wang,Lin; Zhang,Li‑Ying; Zhang,Yu‑Ping; Tian,Yu‑Wang; Fang,Jin‑Nv

doi:10.3892/etm.2015.2196

Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer

Authors:
- Chun‑Wei Xu
- Gang Wang
- Wu‑Long Wang
- Wen‑Bin Gao
- Chuan‑Jun Han
- Jing‑Shan Gao
- Yang Li
- Lin Wang
- Li‑Ying Zhang
- Yu‑Ping Zhang
- Yu‑Wang Tian
- Jin‑Nv Fang
View Affiliations

Affiliations: Department of Pathology, The General Military Hospital of Beijing PLA, Beijing 100700, P.R. China, Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, P.R. China, Graduate School of Dalian University, Dalian, Liaoning 116622, P.R. China, Department of Clinical Medicine, Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Department of Oncology, The General Military Hospital of Beijing PLA, Beijing 100700, P.R. China, Department of Pathology, Shanxi Da Hospital, Shanxi Academy of Medical Sciences, Taiyuan, Shanxi 030001, P.R. China, Department of Pathology, The People's Hospital of Weifang, Weifang, Shandong 261041, P.R. China, Department of Medicine, Yanbian University, Yanji, Jilin 133002, P.R. China
Published online on: January 21, 2015 https://doi.org/10.3892/etm.2015.2196
Pages: 880-884

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the association between epidermal growth factor receptor (EGFR) gene mutations and excision repair cross‑complementing protein 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) mRNA expression in non‑small cell lung cancer (NSCLC) tissue. The quantitative polymerase chain reaction was used to detect EGFR mutations, and ERCC1 and RRM1 mRNA expression in 257 cases of NSCLC. In the NSCLC samples the EGFR mutation rate was 49.03% (126/257). The rate was higher in females and non‑smoking patients (P<0.05). High expression of ERCC1 mRNA was observed in 47.47% of the samples (122/257), while a high RRM1 mRNA expression was observed in 61.87% of the samples (159/257). In comparison with patients with NSCLC without EGFR mutations, patients with EGFR mutations had significantly lower levels of ERCC1 mRNA expression (P<0.05); however, EGFR mutations and expression levels of RRM1 mRNA were not correlated in NSCLC tissues (P>0.05). In addition, ERCC1 mRNA expression was not correlated with the expression levels of RRM1 mRNA (P>0.05). In conclusion, patients with NSCLC with EGFR mutations tend to have a low expression of ERCC1 mRNA and may potentially benefit from platinum‑based chemotherapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cao C, Lu S, Sowa A, et al: Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett. 266:249–262. 2008. View Article : Google Scholar : PubMed/NCBI
4	Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 59(2 Suppl): 21–26. 2004. View Article : Google Scholar : PubMed/NCBI
5	Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
6	Chan SK, Gullick WJ and Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer. 42:17–23. 2006. View Article : Google Scholar
7	Simon GR, Ismail-Khan R and Bepler G: Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 39:1318–1328. 2007. View Article : Google Scholar : PubMed/NCBI
8	Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 38:217–227. 2002. View Article : Google Scholar : PubMed/NCBI
9	Su C, Zhou S, Zhang L, et al: ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol. 28:1411–1417. 2011. View Article : Google Scholar
10	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
11	Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
12	Bepler G, Kusmartseva I, Sharma S, et al: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 24:4731–4737. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
14	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
15	Riely GJ, Pao W, Pham D, et al: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 12:839–844. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
17	Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 17:1818–1825. 2006. View Article : Google Scholar : PubMed/NCBI
18	Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007. View Article : Google Scholar : PubMed/NCBI
19	Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004. View Article : Google Scholar
20	Deng QH, Qiu Y, Mo MC, et al: EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 33:508–512. 2011.(In Chinese). PubMed/NCBI
21	Lin XY, Chen Y and Chen ZZ: Expression of ERCC1 and RRM1 in non-small cell lung cancer (NSCLC) and clinical prognosis. Fujian Yike Daxue Xuebao. 45:10–14. 2011.(In Chinese).
22	Gandara DR, Grimminger P, Mack PC, et al: Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 5:1933–1938. 2010. View Article : Google Scholar : PubMed/NCBI
23	Mitsudomi T, Morita S, Yatabe Y, et al: West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
24	Reynolds C, Obasaju C, Schell MJ, et al: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 27:5808–5815. 2009. View Article : Google Scholar : PubMed/NCBI
25	Simon GR, Schell MJ, Begum M, et al: Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 118:2525–2531. 2012. View Article : Google Scholar :
26	Hu YY, Zhang DB, Dong YG, et al: The protein expression and the significance of RRM1 and ERCC1 in non-small cell lung cancer. Shandong Yi Yao. 52:1–3. 2012.(In Chinese).